Published Reported
FDA Opens TRT Pathway for Low Libido in Men (2026)
On April 16, 2026, the FDA announced it would accept supplemental NDAs for testosterone products to treat low libido in men with idiopathic hypogonadism, with a sponsor contact deadline of April 30, 2026.